Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Open-Label, Active-Controlled, Superiority Trial of EG007, Added to the Combination of Lenvatinib Plus Pembrolizumab vs. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Conditions
Interventions
EG-007
Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection
+1 more
Start Date
December 1, 2026
Primary Completion Date
December 1, 2027
Completion Date
December 1, 2027
Last Updated
December 8, 2025
NCT05112991
NCT06584032
NCT01289041
NCT01379534
Lead Sponsor
Evergreen Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions